Transition from IV to nebulised iloprost therapy as a short and long term treatment for pulmonary hypertension

I. Armstrong, F. Guarasci, L. Martin, E. A. Taylor, N. Hamilton, D. Kiely (Sheffield, United Kingdom)

Source: Annual Congress 2003 - Pulmonary hypertension
Session: Pulmonary hypertension
Session type: Poster Discussion
Number: 3662
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Armstrong, F. Guarasci, L. Martin, E. A. Taylor, N. Hamilton, D. Kiely (Sheffield, United Kingdom). Transition from IV to nebulised iloprost therapy as a short and long term treatment for pulmonary hypertension. Eur Respir J 2003; 22: Suppl. 45, 3662

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Intravenous iloprost as "rescue therapy" in patients with severe primary pulmonary hypertension deteriorating while on chronic aerosolized iloprost therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 705s
Year: 2004

Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application
Source: Eur Respir J 2006; 28: Suppl. 50, 384s
Year: 2006

Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 18: 247
Year: 2001


Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 1334-1335
Year: 2001


Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 324s
Year: 2001

Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001



Long term benefit of sildenafil in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009

Low dose intravenous iloprost therapy in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006

Long term use of imatinib in patients with severe pulmonary arterial hypertension
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010

Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol
Source: Eur Respir J 2001; 18: Suppl. 33, 323s
Year: 2001

A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension
Year: 2010



One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 324s
Year: 2001

Long-term continuous subcutaneous treprostinil therapy for pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 461s
Year: 2003

Inhaled iloprost for the treatment of pulmonary hypertension
Source: Eur Respir Rev 2009; 18: 29-34
Year: 2009


Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 370s
Year: 2002

Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence
Source: Eur Respir J 2009; 34: 7-9
Year: 2009


Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009


Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011

High dose short course of inhaled corticosteroid administration may prevent home oxygen therapy in neonatal chronic lung disease
Source: Eur Respir J 2003; 22: Suppl. 45, 140s
Year: 2003

Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
Source: Eur Respir J, 55 (6) 1902418; 10.1183/13993003.02418-2019
Year: 2020